Sage Supernus Drug Patent Portfolio
Sage Supernus owns 1 orange book drug protected by 8 US patents Given below is the list of Sage Supernus's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10940156 | Neuroactive steroids, compositions, and uses thereof | 08 Mar, 2037 | Active |
| US10251894 | Anticonvulsant activity of steroids | 27 Nov, 2033 | Active |
| US10322139 | Neuroactive steroid formulations and methods of treating CNS disorders | 23 Jan, 2033 | Active |
| US10117951 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US7635773 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US8410077 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US9200088 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US9750822 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
Latest Legal Activities on Sage Supernus's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sage Supernus.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 21 Aug, 2025 | US10322139 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 25 Feb, 2025 | US10322139 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Feb, 2025 | US9750822 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Sep, 2024 | US8410077 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Aug, 2024 | US10940156 |
| Application ready for PDX access by participating foreign offices | 29 May, 2024 | US8410077 |
| Application ready for PDX access by participating foreign offices | 24 May, 2024 | US7635773 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 May, 2023 | US9200088 |
| Correspondence Address Change | 04 Dec, 2022 | US10117951 |
| Correspondence Address Change | 04 Dec, 2022 | US9750822 |
| Correspondence Address Change | 04 Dec, 2022 | US7635773 |
| Correspondence Address Change | 04 Dec, 2022 | US8410077 |
| Correspondence Address Change | 04 Dec, 2022 | US9200088 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 Nov, 2022 | US10322139 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Sep, 2022 | US10251894 |
Sage Supernus Drug Patents' Oppositions Filed in EPO
Sage Supernus drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 08, 2020, by Dr. Schön, Neymeyr & Partner Patentanwälte Mbb. This opposition was filed on patent number EP13740743A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP13740743A | Jul, 2020 | Dr. Schön, Neymeyr & Partner Patentanwälte mbB | Granted and Under Opposition |
Sage Supernus's Family Patents
Sage Supernus Drug List
Given below is the complete list of Sage Supernus's drugs and the patents protecting them.
1. Zulresso
Zulresso is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10940156 | Neuroactive steroids, compositions, and uses thereof |
08 Mar, 2037
(10 years from now)
| Active |
| US10251894 | Anticonvulsant activity of steroids |
27 Nov, 2033
(7 years from now)
| Active |
| US10322139 | Neuroactive steroid formulations and methods of treating CNS disorders |
23 Jan, 2033
(6 years from now)
| Active |
| US10117951 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(2 years from now)
| Active |
| US7635773 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(2 years from now)
| Active |
| US8410077 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(2 years from now)
| Active |
| US9200088 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(2 years from now)
| Active |
| US9750822 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zulresso's drug page